Antisoma zu alten Höhen ?

Kurs ist nun schon mal bei 0,09€ und nur Käufe!

We announced on 29 March that our unaudited cash position as of the end of February 2010 was GBP 45.1 million.


Ah heheh okayyyy.... !!!!

dann kann man mit einem Kauf ja nichts falsch machen    imo

Schon fast 2 mill shares getraded in London...wow !!! :-)

Das geht erst los   ...

bigcharts.marketwatch.com/charts/...;rand=3078&mocktick=1" style="max-width:560px" />

bigcharts.marketwatch.com/charts/...p;rand=3078&mocktick=1

http://bigcharts.marketwatch.com/charts/...mp;rand=851&mocktick=1

 

 

ZWEIEINHALB MILLIONEN SHARES SCHON in nedmal 2 Stunden....

Antisoma (LSE:ASM)
Last Price (USD) $7.00
Change  0.9 (14.75%)
Bid 6.95
Ask 7.00
Volume 2,542,365
Days Range 6.25 - 7.20
Last Trade 6/4/2010 4:47:23 AM

PPS in GBp !!!

muss arbeiten...da kann sowas schon mal vorkommen :-)

Rattert mal jemand die 7 weg dann fliegen wir weiter...danke !

imway2fat.files.wordpress.com/2009/04/cat-wit-big-eyes.jpg" style="max-width:560px" />

12,0178 PENCE   ??

650mill Shares / 45mill cash ?

Wir traden unter Cash/Aktie ??????

14.44 Pence ?
hat jemand genauere zahlen ???

Rechenfehler...

Cash / Aktie müsste so ca. 8 pence sein..

Also wird knapp am Geld jetzt ?
Was fürn Witz..da ist kein bisschen Fantasie mit eingepreist..hehhee

Wieviele Aktien sind denn genau draussen ??

charttechnische Wiederstände naja................
.............als Wiederstände werden sich jetzte wohl eher die Runden Marken erweisen  wie die 0,1...0,15....usw

dann wird weitergeflogen ! :-)

Bid 6.85 Ask 7.10


Im Bigchart intraday 1 minute war ein spike bis 7.40 !!!
bigcharts.marketwatch.com/charts/...mp;rand=851&mocktick=1

http://www.proactiveinvestors.com/companies/news/...by-fda--6296.html

 

Antisoma’s novel leukaemia treatment fast-tracked by FDA

Cancer focused biotechnology company, Antisoma (LON:ASM, OTC: ATSMY) told investors that its novel leukaemia treatment – the AS1413 DNA intercalator – has been granted a Fast Track designation by the US Food and Drug Administration (FDA).

The news has been welcomed by investors as the company’s shares advanced over 6.5% on the London Stock Exchange this morning.

FDA Fast Track designated drugs ordinarily qualify for Priority Review - an expedited review process available to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. The novel DNA intercalator, AS1413 (amonafide L-malate), is being developed for the treatment of secondary acute myeloid leukaemia (secondary AML).

“This drug could represent a major advance in the options available to patients with secondary AML, and we look forward to completing the ongoing phase III trial and sharing the data with FDA and other regulators", Antisoma Chief Executive Glyn Edwards commented. "We're very pleased to have gained FDA Fast Track status for AS1413”.

The FDA's Fast Track programme is designed to facilitate the development of new drugs that have shown the potential to address an unmet medical need in a serious or life-threatening disease. The drug already has orphan drug status in both the US and the EU for the treatment of AML.

Bid 7.05 Ask 7.10
Volume 4,157,912


Bid stacking up...woot woot !!!

null

schnell.
Jeden Tag 8 bis 10% ist ok.